白利辛霉素 | 57760-36-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 白利辛霉素
• 英文名称: Alborixin
• 英文别名: (2R)-2-[(2S,3S,5R,6S)-6-[(2R,3S)-3-[(2R,5S,6R)-6-[[(2R,3S,5R,6R)-6-[(R)-[(2S,5S)-5-[(2R,3R,5S)-5-[(2R,5R,6S)-6-ethyl-5-hydroxy-5-methyloxan-2-yl]-2-hydroxy-3,5-dimethyloxolan-2-yl]-5-methyloxolan-2-yl]-hydroxymethyl]-6-hydroxy-3,5-dimethyloxan-2-yl]methyl]-6-hydroxy-5-methyloxan-2-yl]-2-hydroxybutyl]-3,5-dimethyloxan-2-yl]propanoic acid
• CAS: 57760-36-8
• 化学式: C₄₈H₈₄O₁₄
• 分子量: 885.2
• InChiKey: WWDHGOLBPBWCNJ-GXXSWWTOSA-N

物化性质

• 熔点：
  100-105°
• 比旋光度：
  20 -7° (c = 4 in acetone)
• 沸点：
  929.8±65.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  62
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.98
• 拓扑面积：
  214
• 氢给体数：
  7
• 氢受体数：
  14

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：SPROTT KEVIN

  公开号：WO2013103993A1

  公开（公告）日：2013-07-11

  Salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Dosage forms and kits comprising salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Methods of using salinomycin analogs, pharmaceutically acceptable compositions, dosage forms, and kits for the treatment of proliferative diseases, e.g., cancer, or microbial infections in a subject

  萨利诺霉素类似物及含有萨利诺霉素类似物的药物可接受组成物。包含萨利诺霉素类似物的剂型和套件以及含有萨利诺霉素类似物的药物可接受组成物。使用萨利诺霉素类似物，药物可接受组成物，剂型和套件的方法，用于治疗增生性疾病，如癌症，或受体内微生物感染。
• Method of immobilizing membrane-associated molecules
  申请人：Brennan D. John

  公开号：US20050032246A1

  公开（公告）日：2005-02-10

  The present invention relates to methods of immobilizing membrane-associated molecules within a sol-gel matrix. The membrane-associated molecule is embedded in the bilayer of a liposome. The molecule-liposome assembly remains functionally intact when it is immobilized within a protein and membrane-compatible sol-gel derived from polyol silane precursors or sodium silicate. The activity and stability of the entrapped membrane-associated molecule was significantly improved in macroporous silica.

  本发明涉及将膜相关分子固定在溶胶-凝胶基质中的方法。膜相关分子被嵌入到脂质体的双层中。当分子-脂质体组装体被固定在由聚醇硅烷前体或硅酸钠制成的蛋白质和膜兼容性溶胶-凝胶中时，组装体仍然保持功能完整。在大孔径硅胶中，被困住的膜相关分子的活性和稳定性得到了显着提高。
• METHOD OF IMMOBILIZING MEMBRANE-ASSOCIATED MOLECULES
  申请人：Brennan John D.

  公开号：US20080261825A1

  公开（公告）日：2008-10-23

  The present invention relates to methods of immobilizing membrane-associated molecules within a sol-gel matrix. The membrane-associated molecule is embedded in the bilayer of a liposome. The molecule-liposome assembly remains functionally intact when it is immobilized within a protein and membrane-compatible sol-gel derived from polyol silane precursors or sodium silicate. The activity and stability of the entrapped membrane-associated molecule was significantly improved in macroporous silica.

  本发明涉及将膜相关分子固定在溶胶-凝胶基质中的方法。膜相关分子嵌入了脂质体的双层中。当分子-脂质体组装体被固定在由聚醇硅烷前体或硅酸钠制备的蛋白质和膜兼容性溶胶-凝胶中时，该组装体仍然功能完整。在大孔径硅胶中，包埋的膜相关分子的活性和稳定性得到了显著改善。
• THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE
  申请人：Sprott Kevin

  公开号：US20140371285A1

  公开（公告）日：2014-12-18

  Salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Dosage forms and kits comprising salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Methods of using salinomycin analogs, pharmaceutically acceptable compositions, dosage forms, and kits for the treatment of proliferative diseases, e.g., cancer, or microbial infections in a subject

  盐酸链霉素类似物及其药学上可接受的组成物。包含盐酸链霉素类似物和药学上可接受的组成物的剂型和套装。使用盐酸链霉素类似物、药学上可接受的组成物、剂型和套装的方法，用于治疗受体内增生性疾病，例如癌症或微生物感染。
• THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE
  申请人：VERASTEM, INC.

  公开号：US20140336248A1

  公开（公告）日：2014-11-13

  Aqueous compositions comprising salinomycin, or a pharmaceutically acceptable salt thereof, miscible organic solvents, and solubilizers and/or emulsifying agents are disclosed. The formulations disclosed herein are useful in the treatment of cancer, especially cancers associated with cancer stem cells or cancerous mesenchymal cells. The method of treating a subject may further comprise identifying a subject having a disorder suitable for treatment with the aqueous compositions described, comprising detecting one or more biomarkers predictive of the prevalence of a cancer having or enriched for cancer stem cells (CSCs).

  本文披露了包含沙利霉素或其药学上可接受的盐、可混合有机溶剂以及溶解剂和/或乳化剂的水性组合物。本文所披露的配方在治疗癌症方面有用，尤其是与癌症干细胞或癌性间充质细胞相关的癌症。治疗对象的方法还可以包括确定适合使用所述水性组合物治疗的患者，包括检测一个或多个预测具有或富集癌症干细胞（CSCs）的癌症的普遍性的生物标志物。